A174900 Stock Overview
AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AbClon Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩16,000.00 |
| 52 Week High | ₩25,800.00 |
| 52 Week Low | ₩10,950.00 |
| Beta | 0.16 |
| 1 Month Change | -16.88% |
| 3 Month Change | 20.48% |
| 1 Year Change | -14.89% |
| 3 Year Change | -41.18% |
| 5 Year Change | -48.88% |
| Change since IPO | 23.08% |
Recent News & Updates
Shareholder Returns
| A174900 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.6% | 1.9% | 2.2% |
| 1Y | -14.9% | 6.5% | 5.4% |
Return vs Industry: A174900 underperformed the KR Biotechs industry which returned 5.7% over the past year.
Return vs Market: A174900 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
| A174900 volatility | |
|---|---|
| A174900 Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A174900's share price has been volatile over the past 3 months.
Volatility Over Time: A174900's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | n/a | www.abclon.com |
AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.
AbClon Inc. Fundamentals Summary
| A174900 fundamental statistics | |
|---|---|
| Market cap | ₩262.77b |
| Earnings (TTM) | -₩12.77b |
| Revenue (TTM) | ₩3.08b |
85.2x
P/S Ratio-20.6x
P/E RatioIs A174900 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A174900 income statement (TTM) | |
|---|---|
| Revenue | ₩3.08b |
| Cost of Revenue | ₩897.84m |
| Gross Profit | ₩2.18b |
| Other Expenses | ₩14.95b |
| Earnings | -₩12.77b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -777.29 |
| Gross Margin | 70.88% |
| Net Profit Margin | -414.09% |
| Debt/Equity Ratio | 46.0% |
How did A174900 perform over the long term?
See historical performance and comparison